Tianjin Chase Sun Pharmaceutical Co.,Ltd (SHE:300026)

Market Cap	11.00B +3.4%
Revenue (ttm)	5.49B -2.4%
Net Income	-66.13M
EPS	-0.03
Shares Out	3.00B
PE Ratio	n/a
Forward PE	n/a
Dividend	0.03 (0.82%)
Ex-Dividend Date	Jun 24, 2025

Volume	76,078,236
Average Volume	42,500,773
Open	3.690
Previous Close	3.660
Day's Range	3.620 - 3.780
52-Week Range	3.110 - 4.490
Beta	0.13
RSI	54.57
Earnings Date	Apr 21, 2026

About SHE:300026

Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of various pharmaceutical products in China and internationally. The company provides Chinese medicine formula granules, finished drugs, raw materials, medical devices and excipients, medical and health services, as well as smart supply chain for pharmaceuticals and medical devices. It serves the fields of immunity, cardiovascular and cerebrovascular diseases, respiratory system, and neurodegenerative diseases. The company was founded in 1996 ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 5,297
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300026

Financial Performance

In 2024, SHE:300026's revenue was 5.78 billion, a decrease of -5.34% compared to the previous year's 6.11 billion. Earnings were 21.47 million, a decrease of -95.76%.